SLYND Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Slynd, and when can generic versions of Slynd launch?
Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-five patent family members in twenty-nine countries.
The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.
DrugPatentWatch® Generic Entry Outlook for Slynd
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 28, 2031. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There is one tentative approval for the generic drug (drospirenone), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for SLYND
| International Patents: | 65 |
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Patent Applications: | 2,065 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SLYND |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SLYND |
| What excipients (inactive ingredients) are in SLYND? | SLYND excipients list |
| DailyMed Link: | SLYND at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SLYND
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for SLYND
Paragraph IV (Patent) Challenges for SLYND
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SLYND | Tablets | drospirenone | 4 mg | 211367 | 1 | 2022-01-07 |
US Patents and Regulatory Information for SLYND
SLYND is protected by thirteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SLYND is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SLYND
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SLYND
When does loss-of-exclusivity occur for SLYND?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1670
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 11273605
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2012033391
Estimated Expiration: ⤷ Sign Up
Patent: 2019008317
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 03721
Estimated Expiration: ⤷ Sign Up
Patent: 03062
Estimated Expiration: ⤷ Sign Up
Patent: 61421
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 12003685
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 40328
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0200155
Estimated Expiration: ⤷ Sign Up
Patent: 0220332
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 22544
Estimated Expiration: ⤷ Sign Up
Patent: 25061
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 12012359
Estimated Expiration: ⤷ Sign Up
Patent: 15032906
Estimated Expiration: ⤷ Sign Up
Patent: 15032911
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8680
Estimated Expiration: ⤷ Sign Up
Patent: 1291372
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Patent: 56186
Estimated Expiration: ⤷ Sign Up
France
Patent: C1020
Estimated Expiration: ⤷ Sign Up
Patent: C1031
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1200336
Estimated Expiration: ⤷ Sign Up
Patent: 1200336A
Estimated Expiration: ⤷ Sign Up
Patent: 1200336B
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 47689
Estimated Expiration: ⤷ Sign Up
Patent: 58176
Estimated Expiration: ⤷ Sign Up
Patent: 000016
Estimated Expiration: ⤷ Sign Up
Patent: 200018
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 10159
Estimated Expiration: ⤷ Sign Up
Patent: 13529665
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 2021523
Estimated Expiration: ⤷ Sign Up
Patent: 2022513
Estimated Expiration: ⤷ Sign Up
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 9952
Estimated Expiration: ⤷ Sign Up
Patent: 4971
Estimated Expiration: ⤷ Sign Up
Patent: 12014629
Estimated Expiration: ⤷ Sign Up
Patent: 19004393
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5176
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 20015
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 130780
Estimated Expiration: ⤷ Sign Up
Patent: 161410
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 826
Estimated Expiration: ⤷ Sign Up
Patent: 027
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1209743
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2164693
Estimated Expiration: ⤷ Sign Up
Patent: 2210982
Estimated Expiration: ⤷ Sign Up
Patent: 2539030
Estimated Expiration: ⤷ Sign Up
Patent: 130048227
Estimated Expiration: ⤷ Sign Up
Patent: 170085604
Estimated Expiration: ⤷ Sign Up
Patent: 190073598
Estimated Expiration: ⤷ Sign Up
Patent: 210013663
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 77886
Estimated Expiration: ⤷ Sign Up
Patent: 08657
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SLYND around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ecuador | SP15032911 | COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (DIVISIONAL 1 DE SOLICITUD No. SP-12-12359 PCT) | ⤷ Sign Up |
| Mexico | 2019004393 | COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.) | ⤷ Sign Up |
| Lithuania | 3632448 | ⤷ Sign Up | |
| Guatemala | 201200336 | COMPOSICIÒN FARMACÈUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO | ⤷ Sign Up |
| South Korea | 102210982 | ⤷ Sign Up | |
| Mexico | 364971 | COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SLYND
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2588114 | 19/2020 | Austria | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON; NAT. REGISTRATION NO/DATE: 139227 20191206; FIRST REGISTRATION: DK 31332 (MITTEILUNG) 20191022 |
| 1214076 | C01214076/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| 3632448 | 22C1031 | France | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONE; NAT. REGISTRATION NO/DATE: NL49691 20191121; FIRST REGISTRATION: DK - 31332 20191016 |
| 0398460 | SPC/GB04/032 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310 |
| 2588114 | PA2021523 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONAS; REGISTRATION NO/DATE: 61678 20191016 |
| 2588114 | 122021000065 | Germany | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON; NAT. REGISTRATION NO/DATE: 7002248.00.00 20210426; FIRST REGISTRATION: DK 61678 20191016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
